ES2526521T3 - Composiciones de antibiótico para el tratamiento del oído - Google Patents

Composiciones de antibiótico para el tratamiento del oído Download PDF

Info

Publication number
ES2526521T3
ES2526521T3 ES10176412.4T ES10176412T ES2526521T3 ES 2526521 T3 ES2526521 T3 ES 2526521T3 ES 10176412 T ES10176412 T ES 10176412T ES 2526521 T3 ES2526521 T3 ES 2526521T3
Authority
ES
Spain
Prior art keywords
ear
treatment
antibiotic compositions
influenzae
lactamase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10176412.4T
Other languages
English (en)
Inventor
Gerald Cagle
Robert L. Abshire
David W. Stroman
John M. Yanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Pharmaceuticals Ltd
Original Assignee
Alcon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2526521(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Pharmaceuticals Ltd filed Critical Alcon Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2526521T3 publication Critical patent/ES2526521T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Moxifloxacina o un hidrato o sal farmacéuticamente útil de la misma para su uso en el tratamiento tópico o prevención de infecciones óticas asociadas con P. aeruginosa, H. influenzae / ß-lactamasa positivo o H. influenzae / ß-lactamasa negativo

Description

imagen1
imagen2
imagen3
imagen4

Claims (1)

  1. imagen1
ES10176412.4T 1998-09-30 1999-09-29 Composiciones de antibiótico para el tratamiento del oído Expired - Lifetime ES2526521T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10250498P 1998-09-30 1998-09-30
US10250698P 1998-09-30 1998-09-30
US102504P 1998-09-30
US102506P 1998-09-30

Publications (1)

Publication Number Publication Date
ES2526521T3 true ES2526521T3 (es) 2015-01-13

Family

ID=26799441

Family Applications (4)

Application Number Title Priority Date Filing Date
ES10178657.2T Expired - Lifetime ES2519190T3 (es) 1998-09-30 1999-09-29 Composiciones de antibiótico para el tratamiento ocular
ES99956504T Expired - Lifetime ES2207307T3 (es) 1998-09-30 1999-09-29 Composiciones antibioticas para el tratamiento de los ojos.
ES14176366.4T Expired - Lifetime ES2602956T3 (es) 1998-09-30 1999-09-29 Composiciones de antibiótico para tratamiento de conjuntivitis
ES10176412.4T Expired - Lifetime ES2526521T3 (es) 1998-09-30 1999-09-29 Composiciones de antibiótico para el tratamiento del oído

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES10178657.2T Expired - Lifetime ES2519190T3 (es) 1998-09-30 1999-09-29 Composiciones de antibiótico para el tratamiento ocular
ES99956504T Expired - Lifetime ES2207307T3 (es) 1998-09-30 1999-09-29 Composiciones antibioticas para el tratamiento de los ojos.
ES14176366.4T Expired - Lifetime ES2602956T3 (es) 1998-09-30 1999-09-29 Composiciones de antibiótico para tratamiento de conjuntivitis

Country Status (18)

Country Link
EP (5) EP2796138B1 (es)
JP (5) JP2002525317A (es)
KR (1) KR101463243B1 (es)
CN (2) CN1184968C (es)
AR (2) AR020661A1 (es)
AT (2) ATE254458T1 (es)
AU (1) AU762827B2 (es)
BR (1) BRPI9914151B1 (es)
CA (3) CA2774207A1 (es)
CY (3) CY1111404T1 (es)
DE (2) DE69943287D1 (es)
DK (5) DK2301541T3 (es)
ES (4) ES2519190T3 (es)
HK (4) HK1038691B (es)
PT (5) PT2301541E (es)
TR (2) TR200100883T2 (es)
TW (1) TWI222361B (es)
WO (1) WO2000018386A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
TR200200737T2 (tr) 1999-09-24 2002-08-21 Alcon, Inc. Siproflaksasin ve deksametazon içeren lokal süspansiyon formülasyonları
DE19962470A1 (de) 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
WO2001089495A2 (en) * 2000-05-19 2001-11-29 Alcon Laboratories, Inc. Antibiotic compositions containing quinolone derivatives for treatment of the eye, ear and nose
AU2001276928A1 (en) 2000-07-26 2002-02-05 Alcon Universal Ltd. Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
JPWO2002040028A1 (ja) * 2000-11-16 2004-03-18 わかもと製薬株式会社 抗菌ゲル化点眼剤
AU2002228660A1 (en) 2000-12-20 2002-07-01 Alcon, Inc Use of amidoamines to treat or prevent acanthamoeba and fungal infections
WO2002049627A2 (en) * 2000-12-20 2002-06-27 Alcon, Inc. Antifungal compositions containing an antibiotic and one or more amidoamines
DK1429780T3 (da) 2001-09-21 2006-02-13 Fremgangsmåde til behandling af mellemoreinfektioner
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
BRPI0514898A (pt) * 2004-09-03 2008-06-24 Piedmont Pharmaceuticals Llc métodos para tratamento e prevenção transmembrana da otite média
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
JP2008523060A (ja) * 2004-12-10 2008-07-03 アルコン，インコーポレイティド 耳感染の処置のための組成物
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
TWI544934B (zh) * 2008-06-09 2016-08-11 愛爾康研究有限公司 含有氟喹諾酮抗生素藥物之經改良藥學組成物
RU2570731C2 (ru) * 2009-07-02 2015-12-10 Алькон Рисерч, Лтд. Композиции, включающие финафлоксации, и способы лечения офтальмологических, ушных или назальных инфекций
BR112012016809A2 (pt) * 2010-01-07 2017-09-26 Novartis Ag método e composições para a aplicação de moxifloxacina ao ouvido
BR112014012885A2 (pt) 2011-12-06 2017-06-13 Alcon Res Ltd composição de gel celulósica com estabilidade de viscosidade aperfeiçoada
RU2472507C1 (ru) * 2012-02-01 2013-01-20 Закрытое акционерное общество "Брынцалов-А" Водный состав на основе моксифлоксацина для парентерального введения
US9504691B2 (en) 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
CN104224802B (zh) * 2014-09-19 2017-12-12 南京优科生物医药研究有限公司 一种盐酸莫西沙星滴耳剂及其制备方法
RU2595837C2 (ru) * 2014-09-29 2016-08-27 Открытое Акционерное Общество "Татхимфармпрепараты" Состав и способ получения глазных капель
WO2017073708A1 (ja) * 2015-10-29 2017-05-04 テイカ製薬株式会社 外用剤
JP2021524861A (ja) * 2018-04-03 2021-09-16 ハイデラバード アイ リサーチ ファウンデーション フルオロキノロン系抗生物質の眼内投与のための粘膜付着性薬物送達システム
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica
AU2021289250A1 (en) * 2020-06-10 2023-02-16 Ocular Science, Inc. Compositions and uses in method for post-operative ocular care
KR102656260B1 (ko) 2022-10-14 2024-04-09 주식회사태준제약 목시플록사신을 포함하는 안과용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223493A (en) 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
JPH03109236A (ja) * 1989-09-22 1991-05-09 Hoya Corp 半導体超微粒子分散ガラスの製造方法
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
TW209865B (es) * 1992-01-10 1993-07-21 Bayer Ag
EP0639070B2 (en) 1992-05-06 2010-09-08 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
DE4424369A1 (de) * 1994-07-11 1996-01-18 Bayer Ag Pyrido[3,2,1.i,j][3,1]benzoxazinderivate
JPH0892241A (ja) * 1994-09-22 1996-04-09 Ss Pharmaceut Co Ltd ５−ヒドラジノキノロンカルボン酸誘導体及びこれを有効成分とする抗菌剤
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
MX9701731A (es) * 1995-06-06 1997-10-31 Bayer Ag Composiciones anti-bacterianas oticas, no-irritantes, no-sensibles y no-toxicas para el oido.
JP3290914B2 (ja) * 1997-03-17 2002-06-10 参天製薬株式会社 眼組織におけるキノロン系抗菌剤の定量装置
ATE220547T1 (de) * 1997-09-25 2002-08-15 Bayer Ag Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
ID28630A (id) 1998-09-23 2001-06-21 Unilever Nv Komposisi-komposisi perawatan oral
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US20020001617A1 (en) * 2000-05-26 2002-01-03 Chang-Hyun Lee Rapidly disintegrating tablet and process for the manufacture thereof

Also Published As

Publication number Publication date
WO2000018386A3 (en) 2000-06-08
EP2301541A1 (en) 2011-03-30
JP5563041B2 (ja) 2014-07-30
EP2796138A1 (en) 2014-10-29
EP2301541B1 (en) 2014-08-20
JP2002525317A (ja) 2002-08-13
ES2602956T3 (es) 2017-02-23
CA2342211C (en) 2009-05-26
JP2012067141A (ja) 2012-04-05
EP2796138B1 (en) 2016-08-17
HK1038691B (zh) 2004-04-23
HK1038691A1 (en) 2002-03-28
CY1111404T1 (el) 2015-08-05
CN1184968C (zh) 2005-01-19
AU1310100A (en) 2000-04-17
BRPI9914151B1 (pt) 2017-10-03
CN100374114C (zh) 2008-03-12
CY1115759T1 (el) 2017-01-25
EP1117401A2 (en) 2001-07-25
PT2301541E (pt) 2014-10-29
EP1384478A1 (en) 2004-01-28
EP2269602A1 (en) 2011-01-05
DE69943287D1 (de) 2011-04-28
DK2796138T3 (en) 2016-12-05
TR200704370T2 (tr) 2007-11-21
ATE254458T1 (de) 2003-12-15
EP1117401B1 (en) 2003-11-19
EP1384478B1 (en) 2011-03-16
WO2000018386A2 (en) 2000-04-06
KR101463243B1 (ko) 2014-12-17
JP2014144982A (ja) 2014-08-14
DK1384478T3 (da) 2011-05-23
JP2009007375A (ja) 2009-01-15
CN1320035A (zh) 2001-10-31
AU762827B2 (en) 2003-07-03
BR9914151A (pt) 2001-06-26
AR081393A2 (es) 2012-08-29
PT2269602E (pt) 2014-12-29
AR020661A1 (es) 2002-05-22
TWI222361B (en) 2004-10-21
TR200100883T2 (tr) 2001-10-22
JP2013018799A (ja) 2013-01-31
CA2342211A1 (en) 2000-04-06
DE69912972T2 (de) 2004-04-22
ES2207307T3 (es) 2004-05-16
CN1650863A (zh) 2005-08-10
HK1150756A1 (en) 2012-01-13
PT1117401E (pt) 2004-03-31
EP2269602B1 (en) 2014-11-19
DK2301541T3 (da) 2014-09-01
BRPI9914151B8 (es) 2021-05-25
CA2774207A1 (en) 2000-04-06
PT1384478E (pt) 2011-05-12
CA2659064A1 (en) 2000-04-06
KR20010075138A (ko) 2001-08-09
HK1150769A1 (en) 2012-01-13
PT2796138T (pt) 2016-09-22
ATE501732T1 (de) 2011-04-15
DK2269602T3 (en) 2014-12-15
CY1115916T1 (el) 2017-01-25
ES2519190T3 (es) 2014-11-06
DE69912972D1 (de) 2003-12-24
HK1059572A1 (en) 2004-07-09
DK1117401T3 (da) 2004-02-23

Similar Documents

Publication Publication Date Title
ES2526521T3 (es) Composiciones de antibiótico para el tratamiento del oído
NO2011025I1 (no) Telavancin, eller et farmasøytisk aksseptabelt salt derav, herunder inkludert telavancin hydroklorid
MX9204132A (es) Composiciones farmaceuticas que contienen rifaximin y procedimiento para su preparacion.
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
BR9606547A (pt) Novos derivados de pirimidona com atividade fungicida
GT200100008A (es) Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
TR199902655A2 (xx) K�k�rt-fonksiyonel poliorganosiloksanlar
CU23367A3 (es) Formulación de moxifloxacino con sal común
PT688789E (pt) Processo de lipopeptideos processo para a sua preparacao e sua utilizacao
RS41904A (en) Macrolides
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
BR9608873A (pt) Inibidores de selectina de moléculas pequenas di e trivalentes
NO950799D0 (no) Oralt administrerbare farmasöytiske preparater
CA2058592A1 (en) Antibacterial agents
CO4940412A1 (es) Antibiotico de carbapenem, composicion y metodo de prepara- cion
AR005642A1 (es) Compuestos antibioticos de cefalosporina, uso de los mismos para preparar composiciones farmaceuticas, dichas composiciones farmaceuticas que los comprenden,compuestos intermediarios de aplicacion en la preparacion de los primeros y metodo para elaborar dichos compuestos intermediarios
NO20041912L (no) Tverrbundede glykopeptid-cefalosporinantibiotika
GEP20084437B (en) Novel lincomycin derivatives possessing antimicrobial activity
BR0209206A (pt) Clatrato de hidrato de azitromicina com 1,2-propileno glicol, processo para a sua preparação e composição farmacêutica compreendendo o mesmo
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
RU98120555A (ru) Профилактика плацентарной недостаточности в условиях перинатального вирусно-бактериального инфицирования
NZ509051A (en) Chemotaxis-inhibiting protein of staphylococcus (CHIPS) and its use
ES2196769T3 (es) Uso topico de loperamide para el tratamiento de infecciones microbianas.
EE200200605A (et) Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks